FDA: Some Companies Having Trouble Performing Design Control Activities
This article was originally published in The Silver Sheet
DESIGN CONTROL CAN PROVE PROBLEMATIC for medical device manufacturers that don't have highly skilled engineers on staff, says CDRH official Al Taylor, speculating that firms that skimp on engineering resources may have played a role in last year's increase in design control citations on FDA warning letters. In particular, FDA has found that manufacturers are struggling with design verification, design validation and design change activities, FDA GMP Expert Kim Trautman says. She adds that last year's jump in recalls suggests that firms aren't “doing the amount of work that [they] need to in this area.” Meanwhile, device manufacturers Thoratec, Philips Consumer Healthcare Solutions and Hitachi Chemical Diagnostics share best practices for design control.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.